Imagine a world where respiratory viruses like the flu and RSV no longer hold us hostage every winter—sounds like science fiction, right? But groundbreaking advances in vaccines are making this a reality, and they're sparking heated debates along the way.
Welcome to the forefront of medical innovation at CHEST 2025, where experts gathered in vibrant Chicago, Illinois, to tackle one of healthcare's biggest challenges: battling respiratory viruses that threaten lives, especially among vulnerable groups. Kristina Crothers, MD, a respected professor in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Washington, shared her insights during an exclusive chat with Pharmacy Times®. As someone deeply involved in pulmonary health, Crothers illuminated the latest strides in vaccines for viruses such as influenza and respiratory syncytial virus (RSV). She emphasized not just the scientific breakthroughs, but also the crucial role of building trust to boost vaccine acceptance among those who need it most—like older adults, immunocompromised individuals, and those at high risk for severe illness.
Before we dive into the details, it's important to note that while Crothers serves with the US Department of Veterans Affairs (VA), her thoughts here are entirely her own and do not represent the VA.
In the interview, Pharmacy Times® kicked things off by asking about the most notable recent developments in vaccines for respiratory viruses like influenza and RSV. Crothers, introducing herself warmly, explained that one major leap forward is simply having effective RSV vaccines on the market. For beginners wondering what RSV is, think of it as a common virus that can cause serious lung infections, particularly in infants and the elderly—similar to a bad cold on steroids. Early attempts at RSV vaccines backfired, leading to worse outcomes for vaccinated people, which understandably halted progress for decades. But here's where it gets controversial: those initial failures raised valid concerns about vaccine safety, and some skeptics still question if rushing into new tech is worth the risk. Today, though, pre-fusion RSV vaccines—designed to target the virus in its natural shape before it fuses with cells—have revolutionized protection, offering much safer and more reliable options.
For influenza, another respiratory culprit that mutates rapidly and causes annual outbreaks, advancements include high-dose vaccines (which pack a stronger punch to stimulate the immune system) and adjuvanted ones (enhanced with additives to boost effectiveness). And on the horizon? mRNA platforms, the same technology behind some COVID-19 vaccines, which allow for quicker customization against specific strains. Imagine tailoring a flu shot to match the viruses circulating in your area that season—it's like having a bespoke suit for your immune system.
Shifting gears to how these innovations benefit high-risk populations, Crothers highlighted several key improvements. Take the higher-dose flu vaccines, for example; they provide better immune responses in older adults whose natural defenses weaken with age. Adjuvanted protein vaccines not only amplify immunity but may also extend protection longer, reducing the need for frequent boosters. Meanwhile, mRNA technology enables rapid development of vaccines targeted to emerging threats, ensuring they're ready when new strains appear. Pre-fusion F protein vaccines, currently a game-changer for RSV, are even being explored for other viruses like those causing pneumonia. For immunocompromised patients—such as those undergoing cancer treatment or living with HIV—these designs mean stronger, more durable immunity, potentially lowering hospitalization rates. To put it simply, these aren't just tweaks; they're targeted enhancements that address the vulnerabilities of those most susceptible to severe infections.
When Pharmacy Times® inquired about progress in clinical trials for new respiratory virus vaccines, Crothers pointed to exciting developments. mRNA-based influenza vaccines are already in trials, showing promising safety profiles so far. This speedier approach lets scientists adapt vaccines on the fly, aiming directly at the strains likely to dominate rather than playing a guessing game months in advance. Picture it as forecasting weather: instead of preparing for a generic storm, you get a jacket designed for the exact blizzard coming your way. Additionally, early-stage trials are underway for vaccines against human metapneumovirus (another respiratory troublemaker, similar to RSV) and parainfluenza viruses, which could broaden our arsenal against a whole family of lung invaders.
The conversation then turned to practical strategies for boosting vaccine uptake in real-world clinical settings—a topic that's tricky but essential. Crothers stressed that providers play a pivotal role by incorporating vaccination talks into routine check-ups. For instance, a doctor might casually mention, "Now that we're updating your records, let's check if you're due for this year's flu shot," framing it as standard preventive care rather than an optional extra. This normalization helps demystify vaccines and makes them feel accessible.
For patients who hesitate—perhaps due to past experiences or misinformation—open dialogue is key. Crothers recommends motivational interviewing, a gentle technique where you ask open-ended questions to uncover their worries. "If you've declined vaccines before, what specifically concerns you?" she might ask. From there, providers can address myths with evidence, comparing the mild risks of side effects (like a sore arm or fatigue) against the far greater dangers of infection, such as pneumonia or hospitalization. Through shared decision-making, weighing pros and cons together, many patients come around. Building a trusting relationship amplifies this; research shows that a recommendation from a familiar, respected doctor often seals the deal. Intriguingly, accepting one vaccine doesn't guarantee acceptance of others—each requires its own conversation, tailored to the individual's fears. And this is the part most people miss: vaccine hesitancy isn't just about ignorance; it's often rooted in valid concerns, like historical vaccine mishaps or fears of overreach. Could it be that emphasizing patient autonomy leads to better trust than mandates?
In wrapping up, Crothers' insights underscore a hopeful yet complex landscape: vaccines are evolving faster than ever, but success hinges on both innovation and empathy. As we push boundaries in science, we're also navigating the minefield of public perception.
What do you think—should vaccine developers prioritize rapid innovation, even if it means occasional setbacks, or focus relentlessly on safety first? Do you believe provider conversations alone can overcome deep-seated hesitancy, or is broader education needed? And how do we balance innovation with ethical concerns? Share your opinions in the comments below—we'd love to hear from you!
Stay up-to-date with the latest in drug updates, treatment guidelines, and pharmacy trends by subscribing to Pharmacy Times® for weekly clinical insights.
